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The Typhoid Fever Surveillance in Africa Program (TSAP) was established in 2009 to ﬁll the data void concerning invasive Salmo-
nella disease in sub-Saharan Africa, and to speciﬁcally estimate the burden of bloodstream infections caused by the key pathogen,
Salmonella enterica serovar Typhi. TSAP has achieved this ambitious target, ﬁnding high incidences of typhoid fever in both rural
and urban populations in several countries in sub-Saharan Africa. The results of TSAP will undoubtedly dictate the direction of
future typhoid fever research in Africa, and at last provides a key piece of the disease burden jigsaw puzzle. With the dawn of
new Vi conjugate vaccines against Salmonella Typhi, the next priority for the typhoid community must be providing the required
data on these vaccines so they can be licensed and provided to those in high-risk groups and locations across sub-Saharan Africa.
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The paucity of epidemiologic data regarding invasive Salmonel-
la disease in sub-Saharan Africa led the World Health Organi-
zation (WHO) in 2008 to call for a continent-wide approach in
generating more accurate disease incidence and antimicrobial
susceptibility data. In 2009, the Bill & Melinda Gates Founda-
tion provided the International Vaccine Institute funding to
launch the Typhoid Fever Surveillance in Africa Program
(TSAP). The aim of TSAP was to ﬁll the data void regarding in-
vasive Salmonella disease in sub-Saharan Africa and speciﬁcally
to estimate the burden of bloodstream infections caused by the
key typhoidal pathogen, Salmonella enterica serovar Typhi.
TSAP was established to provide these data from 13 sentinel
sites in 10 countries in sub-Saharan Africa. It was predicted
that TSAP would provide contemporary information to assess
whether disease incidence was sufﬁcient to warrant the intro-
duction of preventive measures, such as vaccination.
Prior global estimates for the burden of invasive Salmonella
disease found that South-Central and East-Central Asia experi-
enced the highest incidences of typhoid fever, with >100 cases
per 100 000 person-years of observation [1]; Africa was previ-
ously estimated to have a moderate incidence (10–100 cases/
100 000 person-years of observation) [2]. The primary data
from TSAP expand these previous estimations (F. Marks,
V. von Kalckreuth, P. Aaby, et al, submitted), and describe
remarkably high incidence rates in 3 of 13 of the African
surveillance sites. Additionally, high incidence rates were ob-
served speciﬁcally in children <15 years of age in 4 of 13 sites,
and in at least 1 age group in 6 of 13 sites (F. Marks, V. von
Kalckreuth, P. Aaby, et al, submitted). These ﬁgures are compa-
rable to the earlier Diseases of the Most Impoverished program
conducted in Asia [1], and again show that children between the
ages of 2 and 14 years bear the global brunt of the burden of ty-
phoid fever. Signiﬁcantly, the incidence rates of typhoid fever in
many of the TSAP sites were equivalent to, or indeed greater
than, incidences reported in parts of Asia in the early 2000s [1,3].
The ﬁndings and study methodology described in this sup-
plement of Clinical Infectious Diseases will undoubtedly inﬂu-
ence the direction of future typhoid fever research in Africa
and outline many key observations regarding typhoid fever ep-
idemiology on this continent. In addition to high incidence
rates, the focal (site-speciﬁc) nature of the disease in Africa
will have substantial implications on the impact of potential in-
tervention strategies. In the supplement article by Cruz and co-
authors, it is shown that the incidence of typhoid fever in Ghana
was substantially different between adjacent urban and rural
areas [4]. Indeed, a recurring TSAP theme is the variable inci-
dence of typhoid fever between sites, with many rural popula-
tions having similar or higher incidences than urban locations.
These data show that structural improvements in water and san-
itation infrastructure, as well as possible vaccination campaigns,
should not be limited only to densely populated settings.
An additional key TSAP ﬁnding was the substantial preva-
lence of drug resistance and multidrug-resistant strains of
invasive Salmonella spp. circulating in sub-Saharan Africa
(F. Marks, V. von Kalckreuth, P. Aaby, et al, submitted) [5].No-
tably, a high prevalence of resistance to ﬁrst-line antimicrobial
agents was identiﬁed in both Salmonella Typhi and nontyphoidal
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Salmonella isolates in some locations. These data are largely re-
ﬂective of other observations in further sites in Africa and Asia
[6–9]. However, the scale of multidrug-resistant strains is con-
cerning and likely to be exacerbated by the combination of the
burden of non-speciﬁc febrile disease with a lack of diagnostic
resources, which leads to the imprecise usage of antimicrobials.
Additional Salmonella Typhi genomics work, also published in
2015, has shown the spread of the H58 lineage into Africa from
Asia, predicting that antimicrobial resistance is a problem that is
likely to increase over time [10].
The work presented in this supplement should raise the
awareness of typhoid fever in rural locations in Africa, and fol-
low-up studies should be conducted in other rural settings that
were not sampled through TSAP. However, further studies, such
as this and other typhoid fever studies, are confounded by the
available diagnostic testing methods [11]. Current blood culture
methods for diagnosing typhoid fever require a reasonable lab-
oratory infrastructure, which is not available in many regions of
sub-Saharan Africa. The upshot in the limitations of diagnosis
is an inability to assess the burden of invasive Salmonella dis-
ease in remote settings with poor water quality and sanitation,
where high disease burdens may now be anticipated. An inabil-
ity to detect patients in remote settings results not only in an
underestimation of the burden of invasive Salmonella disease,
but also the associated disease severity and mortality. Ongoing
investments by the Bill & Melinda Gates Foundation and other
donors will hopefully yield better diagnostic tests that can be
used at the point of care without the need for cumbersome
and insensitive blood culture methods [12].
Invasive Salmonella disease is most prevalent in underprivi-
leged communities with poor quality water supplies and limited
sanitation. Often these communities are overcrowded and have
restricted access to medical care. Preventive vaccination holds
particular potential in reaching marginalized populations. How-
ever, in 2011, the Gavi Alliance stated that no ﬁnancial support
would be provided to countries supporting the introduction of
the presently available Vi polysaccharide vaccines due to insuf-
ﬁcient data on disease burden and limited vaccine efﬁcacy in
children aged <2 years. The lack of Gavi subsidy, combined
with suboptimal performance of Vi polysaccharide vaccines,
led to only very limited use of these vaccines. Five years later,
2 typhoid Vi conjugate vaccines indicated for use in children
aged ≥2 years have been licensed in India, and several more
are in development [13]. Two preconditions have to be met
for Gavi to consider subsidy of typhoid conjugate vaccines:
(1) WHO prequaliﬁcation of a typhoid conjugate vaccine and
(2) WHO recommendations for use in form of a position
paper. For WHO to act, relevant data on the clinical perfor-
mance of the new vaccines need to be published, and manufac-
turers need to show interest in international use of the vaccine
and submit their data ﬁle for prequaliﬁcation. The TSAP study
results show a great need for these vaccines, and hopefully
provide further impetus to move the agenda to make these vac-
cines available to the populations in greatest need.
Possible future vaccination strategies in Africa include preemp-
tive, responsive (in the case of an outbreak), and food handler im-
munization [14]. However, to motivate policymakers to actually
deploy vaccines against invasive Salmonella disease, the research
community must communicate not only the disease burden but
also the effectiveness of vaccination, and the country-speciﬁc risk
factors necessary to identify target groups/areas. Current research
efforts are aimed at developing models that predict risk factors
across sub-Saharan Africa to facilitate the assessment of possible
Salmonella disease burden. However, such models can never re-
place real disease burden data in at-risk countries and communi-
ties, and it is unlikely that health ministries will approve mass
vaccination programs on the basis of modeling data alone. There-
fore, we again highlight the need for functional diagnostic tests
and sustained disease surveillance alongside the genomic tracking
of organisms and genes facilitating antimicrobial resistance.
Perhaps the most critical next activity in invasive Salmonella
disease research is the identiﬁcation of sites in Africa and Asia
with consistently high burdens of disease for which water, san-
itation, and hygiene (WASH) improvements can be implement-
ed in conjunction with, or in comparison to, mass vaccination.
Such studies would begin to quantify a more precise measure of
the impact of WASH on disease incidence, and determine the
extent of vaccination coverage alongside WASH improvements
required for location-speciﬁc elimination of invasive Salmonella
disease. Such data on the impact of the interventions will pro-
vide the most compelling case for decision makers to act upon.
In conclusion, data from the TSAP program have ﬁrmly po-
sitioned invasive Salmonella disease as a public health priority
on the African agenda. With the dawn of Vi conjugate vaccines
and now-reliable incidence ﬁgures in Africa, the typhoid fever
community really now needs to tackle the political issues sur-
rounding typhoid fever immunization if we truly believe that re-
gional elimination is a tangible target.
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